KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Free Cash Flow (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Free Cash Flow data on record, last reported at $57.3 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 58.89% year-over-year to $57.3 million; the TTM value through Dec 2025 reached $150.5 million, down 18.11%, while the annual FY2025 figure was $150.5 million, 18.11% down from the prior year.
  • Free Cash Flow reached $57.3 million in Q4 2025 per PCRX's latest filing, up from $57.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $63.7 million in Q3 2021 and bottomed at -$17.9 million in Q4 2021.
  • Average Free Cash Flow over 5 years is $33.4 million, with a median of $36.3 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: crashed 155.59% in 2021, then soared 385.99% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$17.9 million in 2021, then surged by 303.8% to $36.5 million in 2022, then increased by 25.29% to $45.8 million in 2023, then fell by 21.19% to $36.1 million in 2024, then surged by 58.89% to $57.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $57.3 million in Q4 2025, $57.0 million in Q3 2025, and $1.5 million in Q2 2025.